Business
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital
Term loan adds balance sheet strength and provides financial flexibility to support continued development of pemvidutideGAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE: HTGC), a leader in debt financing for life science companies, for up to $100
About this update from Altimmune, Inc.
[{"type":"image","alt":"Altimmune, Inc","displaySize":"","headline":null,"caption":"Altimmune, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gY.Kxe7ML79dI0xW5370RA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTExNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/767e25bad8979b96701d6a099286a009","width":150,"height":82}},"lazy":false},{"type":"text","content":"Term loan adds balance sheet strength and provides financial flexibility to support continued development of pemvidutide","length":120,"tagName":"p"},{"type":"text","content":"GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE: HTGC), a leader in debt financing for life science companies, for up to $100 million in a credit facility, with a $15 million tranche funded at closing. Additional tranches will become available upon achievement of certain clinical and financial milestones aligned with the Company’s pemvidutide development plans and financing needs.","length":638,"tagName":"p"},{"type":"text","content":"Access to this additional capital strengthens Altimmune’s balance sheet, which included $150 million in cash and cash equivalents as of March 31, 2025, and will support the ongoing development of pemvidutide, Altimmune’s novel GLP-1/glucagon dual receptor agonist. Pemvidutide is currently being studied in IMPACT, a Phase 2b trial in metabolic dysfunction-associated steatohepatitis (MASH), with top-line data expected in Q2 2025. In addition, Phase 2 trials evaluating pemvidutide in Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) are expected to be initiated in the second and third quarters of 2025, respectively.","length":629,"tagName":"p"},{"type":"text","content":"Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune said, “We are excited to partner with Hercules, which has a strong history of funding innovative biopharmaceutical companies. We look forward to working with the Hercules team to maximize the potential of pemvidutide in live...